Shopping Cart
- Remove All
- Your shopping cart is currently empty
BMS-214662 is a selective farnesyl transferase inhibitor with antitumor activity, useful in studies of pancreatic, head and neck, and lung cancers.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $2,270 | 10-14 weeks | |
50 mg | $2,980 | 10-14 weeks | |
100 mg | $4,000 | 10-14 weeks |
Description | BMS-214662 is a selective farnesyl transferase inhibitor with antitumor activity, useful in studies of pancreatic, head and neck, and lung cancers. |
Targets&IC50 | H-Ras:1.3 nM, K-Ras:8.4 nM |
In vitro | BMS-214662 is a potent selective farnesyl transferase (FTI) inhibitor with antitumor activity. [2] BMS-214662 (250 nM, 24h) induces mitochondrial apoptosis in chronic myelogenous leukemia (CmL) stem/progenitor cells, including CD34+38- cells, by activating protein kinase Cbeta. [1] |
In vivo | HCT-116 xenograft mice, BMS-214662 (250 mg/kg intravenously,300 mg/kg or 400 mg/kg orally), induced tumor cell apoptosis. For HCT-116 and EJ-1 tumors, the doses of BMS-214662 required to kill 90% of cloned tumor-forming cells were approximately 75 and 100 mg/kg, respectively. [3] |
Alias | BMS214662 |
Molecular Weight | 489.61 |
Formula | C25H23N5O2S2 |
Cas No. | 195987-41-8 |
Smiles | C([C@H]1N(S(=O)(=O)C2=CC=CS2)CC=3C(N(CC4=CN=CN4)C1)=CC=C(C#N)C3)C5=CC=CC=C5 |
Relative Density. | 1.45 g/cm3 (Predicted) |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | H2O: < 1 mg/mL (insoluble) DMSO: 80 mg/mL (163.4 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.